Literature DB >> 20428216

Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype.

P Neeson1, A Shin, K M Tainton, P Guru, H M Prince, S J Harrison, S Peinert, M J Smyth, J A Trapani, M H Kershaw, P K Darcy, D S Ritchie.   

Abstract

The anti-tumor efficacy of adoptively transferred T cells requires their in vivo persistence and memory polarization. It is unknown if human chimeric antigen receptor (CAR)-expressing T cells can also undergo memory polarization. We examined the functional status of CAR CD8(+) T cells, re-directed to Lewis Y antigen (LeY-T), throughout a period of ex vivo expansion. Immediately before culture CD8(+) T cells comprised a mixture of phenotypes including naive (CD45RA(+)/CCR7(+)/CD27(+)/CD28(+)/perforin-), central memory (CM, CD45RA(-)/CCR7(lo)/CD27(+)/CD28(+)/perforin(lo)), effector memory (EM, CD45RA(-)/CCR7(-)/CD27(+)/CD28(+)/perforin(mod)) and effector (Eff, CD45RA(+)/CCR7(-)/CD27(-)/CD28(-)/perforin(hi)) cells. After transduction and expansion culture of peripheral blood mononuclear cells from normal donors or multiple myeloma patients, CD8(+) LeY-T cells polarized to EM- and CM-like phenotype. CD8(+) LeY-T cells differed from starting CD8(+) CM and EM T cells in that CD27, but not CD28, was downregulated. In addition, CD8(+) LeY-T cells expressed high levels of perforin, similar to starting CD8(+) Eff. CD8(+) LeY-T cells also showed hallmarks of both memory and Eff function, underwent homeostatic proliferation in response to interleukin (IL)-15, and showed interferon (IFN)-γ production and cytotoxicity in response to Le-Y antigen on OVCAR-3 (human ovarian adenocarcinoma) cells. This study confirms CD8(+) LeY-T cells have a CM- and EM-like phenotype and heterogeneous function consistent with potential to persist in vivo after adoptive transfer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428216     DOI: 10.1038/gt.2010.59

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  16 in total

1.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.

Authors:  Yang Xu; Ming Zhang; Carlos A Ramos; April Durett; Enli Liu; Olga Dakhova; Hao Liu; Chad J Creighton; Adrian P Gee; Helen E Heslop; Cliona M Rooney; Barbara Savoldo; Gianpietro Dotti
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

2.  Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.

Authors:  Rashmi Gupta; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

3.  Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

Authors:  David S Ritchie; Paul J Neeson; Amit Khot; Stefan Peinert; Tsin Tai; Kellie Tainton; Karen Chen; Mandy Shin; Dominic M Wall; Dirk Hönemann; Peter Gambell; David A Westerman; Javier Haurat; Jennifer A Westwood; Andrew M Scott; Lucy Kravets; Michael Dickinson; Joseph A Trapani; Mark J Smyth; Phillip K Darcy; Michael H Kershaw; H Miles Prince
Journal:  Mol Ther       Date:  2013-07-08       Impact factor: 11.454

4.  Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.

Authors:  Harjeet Singh; Matthew J Figliola; Margaret J Dawson; Helen Huls; Simon Olivares; Kirsten Switzer; Tiejuan Mi; Sourindra Maiti; Partow Kebriaei; Dean A Lee; Richard E Champlin; Laurence J N Cooper
Journal:  Cancer Res       Date:  2011-05-10       Impact factor: 12.701

Review 5.  Antibodies: At The Nexus of Antigens and Cancer Vaccines.

Authors:  Zenon Steplewski; Magdalena Thurin; Thomas Kieber-Emmons
Journal:  J Infect Dis       Date:  2015-07-15       Impact factor: 5.226

6.  In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.

Authors:  Shicheng Yang; Luca Gattinoni; Gattinoni Luca; Fang Liu; Yun Ji; Zhiya Yu; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Immunol Immunother       Date:  2011-02-09       Impact factor: 6.968

Review 7.  Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.

Authors:  Faroogh Marofi; Heshu Sulaiman Rahman; Zaid Mahdi Jaber Al-Obaidi; Abduladheem Turki Jalil; Walid Kamal Abdelbasset; Wanich Suksatan; Aleksei Evgenievich Dorofeev; Navid Shomali; Max Stanley Chartrand; Yashwant Pathak; Ali Hassanzadeh; Behzad Baradaran; Majid Ahmadi; Hossein Saeedi; Safa Tahmasebi; Mostafa Jarahian
Journal:  Stem Cell Res Ther       Date:  2021-08-20       Impact factor: 6.832

Review 8.  Tumor buster - where will the CAR-T cell therapy 'missile' go?

Authors:  Chunrun Qu; Hao Zhang; Hui Cao; Lanhua Tang; Haoyang Mo; Fangkun Liu; Liyang Zhang; Zhenjie Yi; Lifu Long; Luzhe Yan; Zeyu Wang; Nan Zhang; Peng Luo; Jian Zhang; Zaoqu Liu; Weijie Ye; Zhixiong Liu; Quan Cheng
Journal:  Mol Cancer       Date:  2022-10-19       Impact factor: 41.444

9.  The CD3-zeta chimeric antigen receptor overcomes TCR Hypo-responsiveness of human terminal late-stage T cells.

Authors:  Gunter Rappl; Tobias Riet; Sabine Awerkiew; Annette Schmidt; Andreas A Hombach; Herbert Pfister; Hinrich Abken
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

Review 10.  Induced Pluripotent Stem Cell as a New Source for Cancer Immunotherapy.

Authors:  Farzaneh Rami; Halimeh Mollainezhad; Mansoor Salehi
Journal:  Genet Res Int       Date:  2016-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.